Anacor completes patient enrollment for AN2690 drug study

13th November 2011 (Last Updated November 13th, 2011 18:30)

Anacor Pharmaceuticals has concluded patient enrollment in the first of two Phase 3 trials of a topical anti-fungal product Tavaborole (AN2690), used to treat onychomycosis.

Anacor Pharmaceuticals has concluded patient enrollment in the first of two Phase 3 trials of a topical anti-fungal product Tavaborole (AN2690), used to treat onychomycosis.

The Phase 3 trial includes two double-blind vehicle-controlled trials with two-to-one randomisation between tavaborole and vehicle (the topical formulation without the active ingredient).

As per Special Protocol Assessment with the FDA, the primary efficacy endpoint is a complete cure of the great toenail at week 52.

Anacor Pharmaceuticals CEO David Perry said they hope tavaborole can provide improved standards of care for onychomycosis.

"We have completed enrollment of approximately 600 patients in the first of two Phase 3 trials for Tavaborole. We expect to complete enrollment in our second Phase 3 trial by year-end 2011," Perry added.

The study results are expected by the end of 2012.